4.3 Article

Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents

期刊

PEDIATRIC DIABETES
卷 22, 期 3, 页码 495-502

出版社

WILEY
DOI: 10.1111/pedi.13164

关键词

artificial pancreas (AP); automated insulin delivery (AID); continuous glucose monitoring (CGM); continuous subcutaneous insulin infusion (CSII); fear of hypoglycemia; sensor‐ augmented pump therapy (SAP); sleep

资金

  1. State Council of Higher Education for Virginia (SCHEV) through a Virginia Research Investment Fund (VRIF) grant

向作者/读者索取更多资源

The study found that the use of the automated insulin delivery system Control-IQ had a positive impact on glycemic outcomes in young children with T1D, as well as improvements in parents' sleep and diabetes-specific quality of life.
Background Data on the use of Control-IQ, the latest FDA-approved automated insulin delivery (AID) system for people with T1D 6 years of age or older is still scarce, particularly regarding nonglycemic outcomes. Children with T1D and their parents are at higher risk for sleep disturbances. This study assesses sleep, psycho-behavioral and glycemic outcomes of AID compared to sensor-augmented pump therapy (SAP) therapy in young children with T1D and their parents. Methods Thirteen parents and their young children (ages 7-10) on insulin pump therapy were enrolled. Children completed an initial 4-week study with SAP using their own pump and a study CGM followed by a 4-week phase of AID. Sleep outcomes for parents and children were evaluated through actigraphy watches. Several questionnaires were administered at baseline and at the end of each study phase. CGM data were used to assess glycemic outcomes. Results Actigraphy data did not show any significant change from SAP to AID, except a reduction of number of parental awakenings during the night (p = 0.036). Parents reported statistically significant improvements in Pittsburgh Sleep Quality Index total score (p = 0.009), Hypoglycemia Fear Survey total score (p = 0.011), diabetes-related distress (p = 0.032), and depression (p = 0.023). While on AID, time in range (70-180 mg/dL) significantly increased compared to SAP (p < 0.001), accompanied by a reduction in hyperglycemia (p = 0.001). Conclusions These results suggest that use of AID has a positive impact on glycemic outcomes in young children as well as sleep and diabetes-specific quality of life outcomes in their parents.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据